{"id":"tp-57050","type":"article-newspaper","title":"Incyte Drops Plans for Phase 3 MAESTRA-3 Ovarian Cancer Trial","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/57050","datePublished":"2026-11-13T22:17:53.000Z","dateModified":"2026-11-13T22:17:53.000Z","language":"en","abstract":"The study was designed to test INCB123667 with bevacizumab as first-line maintenance therapy for ovarian cancer.","section":"Business","references":[]}